CoChat

Risk Factors for Chronic Kidney Disease in Adults with Cystic Fibrosis

Open access
Quon, Bradley S., Mayer-Hamblett, Nicole, Aitken, Moira L., Smyth, Alan R., Goss, Christopher H. · 2011 · American Journal of Respiratory and Critical Care Medicine

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Rationale: Adults with cystic fibrosis (CF) possess multiple potential risk factors for chronic kidney disease, including CF-related diabetes (CFRD) and lifetime nephrotoxic drug exposure. Objectives: To determine whether cumulative intravenous (IV) aminoglycoside exposure and CFRD increase the risk of chronic kidney disease in adults with CF. Methods: This was a cohort study using adults (≥ 18 yr) in the CF Foundation registry from 2001–2008. Chronic kidney disease (stage 3 or greater) was defined by an estimated glomerular filtration rate of less than 60 ml/min/1.73 m2. Time-dependent multivariable Cox proportional hazards models were used to determine whether cumulative number of acute pulmonary exacerbations (surrogate for IV aminoglycoside exposure) and CFRD requiring insulin increase the risk of chronic kidney disease, adjusting for confounders. Measurements and Main Results: The study cohort included 11,912 adults with a median follow-up of 4 years. During the study period, 204 subjects had chronic kidney disease, with an annual disease prevalence of 2.3%. Disease prevalence doubled with every 10-year increase in age. CFRD requiring insulin therapy substantially increased the risk of chronic kidney disease (1–4 yr of CFRD requiring insulin vs. no CFRD, hazard ratio [HR] = 2.40, 95% confidence interval [CI] 1.74–3.32; ≥ 5 yr, HR = 4.56, 95% CI 2.84–7.31). Pulmonary exacerbations did not significantly increase the risk of chronic kidney disease (one to five exacerbations vs. none, HR = 0.79, 95% CI 0.56–1.11; six to nine exacerbations, HR = 0.92, 95% CI 0.58–1.46; ≥ 10 exacerbations, HR = 1.16, 95% CI 0.75–1.81). Conclusions: CF-related diabetes is a significant risk factor for chronic kidney disease in adults with CF, but additional studies examining IV aminoglycoside exposure directly are required.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201105-0932oc

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 2

  1. Cystic Fibrosis Foundation Patient Registry 2009 Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2011 [Google Scholar]
  2. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39(Suppl 1):S1–S266 [PubMed] [Google Scholar]

Cited by

See all 90

Metadata

Authors
Quon, B. S., Mayer-Hamblett, N., Aitken, M. L., Smyth, A. R., & Goss, C. H.
Affiliations
  • University of British Columbia (CA)
  • Seattle Children's Hospital (US)
  • University of Washington (US)
  • University of Nottingham (GB)
Corresponding author
Quon, Bradley S.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2011-11
Volume
184
Issue
10
Pages
1147-1152
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2000669626
Cited by
90
References
34
Citations by year
2026: 6 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 9 · 2021: 5 · 2020: 7 · 2019: 4 · 2018: 9 · 2017: 7 · 2016: 5 · 2015: 5 · 2014: 7 · 2013: 3 · 2012: 4
FWCI
4.09
Type
journal article
Language
en
Open access
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • British Columbia Lung Association
  • National Institute for Health and Care Research (PB-PG-1207-15025)
  • National Institutes of Health (P30 DK 089,507, DK089507)
  • National Heart, Lung, and Blood Institute (R01HL103965)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK089507, P30DK089507)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
cystic fibrosis, chronic kidney disease, CF-related diabetes, aminoglycoside nephrotoxicity, pulmonary exacerbations, insulin therapy, risk factors, adults with cystic fibrosis, estimated glomerular filtration rate
MeSH terms
Adolescent, Adult, Age Factors, Aminoglycosides, Anti-Bacterial Agents, Cystic Fibrosis, Diabetic Nephropathies, Female, Humans, Injections, Intravenous, Kidney Failure, Chronic, Longitudinal Studies, Male, Middle Aged, Risk Factors, Time Factors, Prevalence, Confidence Intervals, Proportional Hazards Models, Young Adult, Glomerular Filtration Barrier

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk Factors for Chronic Kidney Disease in Adults with Cystic Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.201105-0932oc
The paper
Quon, B. S., Mayer-Hamblett, N., Aitken, M. L., Smyth, A. R., & Goss, C. H. (2011). Risk Factors for Chronic Kidney Disease in Adults with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201105-0932oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.